Neuren Pharmaceuticals (NURPF) Stock Price, News & Analysis

Company Overview

Neuren Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing treatments for neurodevelopmental disorders and other conditions affecting the central nervous system. The company’s research is centered on therapies intended to address significant unmet medical needs in children and adults.

Neuren’s lead product, trofinetide, was developed for Rett syndrome and received approval from the U.S. Food and Drug Administration in 2023 under the brand name Daybue. Neuren licensed development and commercial rights for trofinetide in North America to Acadia Pharmaceuticals, which markets the therapy in the United States. Neuren may receive royalties and other payments under its agreement with Acadia.

The company is also developing NNZ-2591, an investigational therapy being studied for several rare neurodevelopmental conditions, including Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Neuren conducts or supports research through clinical development programs in the United States and Australia, with commercialization activities for trofinetide handled through its North American partnership.

Key Stats

• Today's Range: C$14.28 to C$14.28
• 50-Day Range: C$13.46 to C$17.00
• 52-Week Range: C$7.70 to C$17.25
• Volume: 5 shs
• Average Volume: 1,604 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Neuren Pharmaceuticals Stock Analysis - MarketRank™

Neuren Pharmaceuticals scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Neuren Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Neuren Pharmaceuticals is -1,596.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neuren Pharmaceuticals is -1,596.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Neuren Pharmaceuticals has a short interest ratio ("days to cover") of 808.02, which indicates bearish sentiment.

Change versus previous month

Short interest in Neuren Pharmaceuticals has recently increased by 23.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neuren Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Neuren Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: N/A

News Sentiment

Neuren Pharmaceuticals has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Neuren Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

1.74% of the stock of Neuren Pharmaceuticals is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:NURPF
• CIK: N/A
• Web: www.neurenpharma.com
• Phone: (139) 092-0480
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A